Skip to content
zameds

Calcium chloride, magnesium chloride, sodium chloride, sodium lactate (Intramed Peritoneal Dyalysis With Dextrose)

Calcium chloride, magnesium chloride, sodium chloride, sodium lactate

Pharmacare limited û woodmead

Every registration of this product has been cancelled.

Registration

Applicant
Pharmacare limited û woodmead
Registrations
1

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Intramed peritoneal dyalysis solution with dextrose 1,5 %

EACH 1000 ml SOLUTION CONTAINS CALCIUM CHLORIDE 0,363 g DEXTROSE, ANHYDROUS 15,O0 g MAGNESIUM CHLORIDE 0,152 g SODIUM CHLORIDE 5,61 g SODIUM LACTATE 5,04 g

1,5 %SolutionD0153D/34/153CancelledNot determinedNone

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

Listings for this ingredient that could not be applied to this product

  • S4: Calcium

    • when indicated for the treatment of hyperphosphataemia; (S0)
    • except in oral preparations or mixtures containing more than1300 mg of calcium per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S1)
    • except in preparations thereof for injection; (S3)
    • except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947).

    Consolidated Schedules 06 July 2026, lines 5618 to 5628

  • S3: Calcium

    • in preparations thereof for injection; (S0)
    • except in oral preparations or mixtures containing more than1300 mg of calcium per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S1)
    • except when indicated for the treatment of hyperphosphataemia; (S4)
    • except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947).

    Consolidated Schedules 06 July 2026, lines 3262 to 3272

  • S1: Calcium

    • in oral preparations or mixtures containing more than 1300 mg of calcium per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S0)
    • except in preparations thereof for injection; (S3)
    • except when indicated for the treatment of hyperphosphataemia; (S4)
    • except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947).

    Consolidated Schedules 06 July 2026, lines 302 to 312

  • S1: Magnesium

    • in oral preparations or mixtures containing more than 250 mg of Magnesium per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S0)

    Consolidated Schedules 06 July 2026, lines 815 to 816

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

Combination product

This product contains more than one active ingredient, so it has no single molecular structure.

SAHPRA documents

SAHPRA has not published a professional information or patient information leaflet for this product.

Background

Loading...
Loading Wikipedia summary

Research articles

Loading...
Loading PubMed articles